Indivior Pharmaceuticals (INDV) Operating Leases (2021 - 2026)

Indivior Pharmaceuticals' Operating Leases history runs 6 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• In Q1 2026, Operating Leases fell 53.33% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (down 53.33% YoY), while the FY2025 annual figure was $22.0 million, down 31.25% from the prior year.
• Operating Leases was $14.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $22.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $34.0 million in Q4 2023 to a low of $14.0 million in Q1 2026.
• Historically, Operating Leases has averaged $26.8 million across 5 years, with a median of $29.0 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Operating Leases grew 17.24% in 2023, then plunged 53.33% in 2026.
• A 5-year view of Operating Leases shows it stood at $29.0 million in 2022, then increased by 17.24% to $34.0 million in 2023, then dropped by 5.88% to $32.0 million in 2024, then sank by 31.25% to $22.0 million in 2025, then slumped by 36.36% to $14.0 million in 2026.
• The last three Operating Leases figures came in at $14.0 million (Q1 2026), $22.0 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.